Johnson & Johnson halts COVID-19 vaccine study as participant falls ill
Category: #health  By Nikita Chaurasia  Date: 2020-10-14
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Johnson & Johnson halts COVID-19 vaccine study as participant falls ill

 

  • Johnson & Johnson had initially planned to enroll over 60,000 participants for its phase 3 clinical trials.
  • Experts claim that clinical pauses are a common aspect and may last only a few days.

U.S.-based multinational pharmaceutical corporation Johnson & Johnson has reportedly paused the study of its COVID-19 vaccine candidate after it had an adverse effect in one of the participants. Sources close to the matter stated that the company has issued an investigation on the unexplained ailment in the participant.

Johnson & Johnson had initially planned to enroll over 60,000 participants in the U.S. as well as other countries for its phase 3 clinical trials. In this context, experts cite that given the size of the company’s COVID-19 vaccine trials, such pauses are a common aspect and may last only a few days.

Johnson & Johnson mentioned in a statement that accidents, illnesses and other adverse medical outcomes are a common part of a clinical study and its safety monitoring panel will review as well as determine the cause of the illness.

Johnson & Johnson also emphasized over the fact that its COVID-19 vaccine study is currently paused and not on a clinical hold. The American pharmaceutical giant added that it is not yet apparent whether the participant who suffered an adverse effect received the potential vaccine or a placebo.

For the record, British pharmaceutical company AstraZeneca plc had also kept its COVID-19 vaccine trials on hold earlier in September, after one of the study participants witnessed an unexpected reaction. Although the study resumed in the United Kingdom a week later, the trials are still kept on hold in the United States.

In other news, Indian biotechnology company Bharat Biotech International Ltd. has reportedly reduced the size of its phase-2 clinical study for COVID-19 vaccine candidate called Covaxin. According to experts, reducing the size of Covaxin’s clinical trial will allow Bharat Biotech to accelerate phase-2 study and possibly initiate the phase 3 trials eventually.

Source Credits –

https://www.statnews.com/2020/10/12/johnson-johnson-covid-19-vaccine-study-paused-due-to-unexplained-illness-in-participant/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Moderna failed to meet FDA’s requirements for COVID-19 booster vaccines

Moderna failed to meet FDA’s requirements for COVID-19 booster vaccines

By Nikita Chaurasia

Scientists from the U.S. Food and Drug Administration (FDA) claimed that Moderna did not meet all the requirements to support the use of COVID-19 booster shots. This is because the first two shots already showed a strong efficacy rate. Documents rel...

Canada’s healthcare sector likely to brace for looming staff shortages

Canada’s healthcare sector likely to brace for looming staff shortages

By Nikita Chaurasia

According to reliable sources, Canada’s overworked healthcare sector is now bracing for upcoming staff shortages and potential layoffs, as the country accelerates its vaccination drive before the deadline. The development comes at a time when l...

Rocket Lab, Kineis sign multi-launch contract for IoT constellation

Rocket Lab, Kineis sign multi-launch contract for IoT constellation

By Nikita Chaurasia

The space industry is booming as new companies with fresh ideas for space-based applications take advantage of declining launch and satellite costs. Out of those firms, Rocket Lab USA bagged a contract to launch 25 satellites on five missions exclusi...